The Pharmaceutical industry is without question driven by the productivity of its R&D. For decades, the European region dominated the pharmaceutical R&D sector. However, the effects of a global recession in 2008-2009 combined with outsourcing, globalization, and ICT advancements levelled the playing field for drug discovery. Emerging economies such China, India, and Korea are now virtually on par with the advancements of giants like Europe and the US, bridging the gap in what is historically an extremely competitive industry. Faced with the threat of being overtaken by such low cost and technologically advancing nations, it is imperative that European pharmaceutical companies counteract the competition with heightened focus in innovative drug discovery technology.
In 2010, much emphasis has been placed on helping Europe climb back to the top of the R&D ladder. The European pharmaceutical sector must currently focus on innovative solutions which can integrate seamlessly with existing technologies and strategies, which are key factors in bringing drugs to market quicker and more effectively. Given the multitude of new pharmaceuctical R& D institutes and the determination of the EU to revive Europe's status as an innovation leader in drug discovery, returns on such R & D investment over the next few years could potentially boom. Leaders in the R & D and Drug Discovery space know that now is the time to commit to drug discovery. The Next Generation Drug Discovery Summit Europe is designed to bridge the growing technological gap between drug discovery and drug development.
"For those interested in emerging drug discovery technologies and concepts, there are few conferences that meet the standards of the NGP series. The conference is professionally organized with a focus on shaping agendas for the individual needs of the attendees."
Ted Torphy, VP Head of External Innovation, Johnson & Johnson